The SVRI will be based initially on the partnership between the following leading institutions, based in different parts of Switzerland:
- Centre Hospitalier Universitaire Vaudois (CHUV)
- Université de Lausanne/Faculté de Biologie et de Médecine (UNIL/FBM)
- Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne
- Institute for Research in Biomedicine (IRB), Bellinzona
- Ludwig Institute for Cancer Research (LICR), Lausanne Branch, Epalinges
- Swiss Tropical and Public Health Institute (Swiss TPH), Basel
These six institutions have a long tradition and a concentration of scientists in the fields of immunology, of HIV, malaria, TB and cancer vaccine development, of virology and of adjuvant/delivery technology. Partnerships with other Swiss institutions competent in the fields of immunology and vaccines will be strongly favoured.
The SVRI is driven by the common goal of international initiatives promoted at a political, corporate and academic level to reduce or eliminate suffering and death due to infectious diseases and cancer.
The SVRI will contribute to this goal through exploration, scientific discovery and translation of the discoveries into effective preventive vaccine strategies and therapeutic vaccine interventions for infectious diseases and for cancer.
